Full-Time

Senior Director of Global Real Estate and Workplace Strategy

Posted on 12/13/2025

Illumina

Illumina

5,001-10,000 employees

Accelerates genomics startups through funding

Compensation Overview

$224.9k - $337.3k/yr

+ Bonus/Commission + Equity

No H1B Sponsorship

San Diego, CA, USA

In Person

Category
Real Estate (1)
Required Skills
Risk Management
Financial Modeling
Requirements
  • Typically requires a Bachelor’s degree and a minimum of 20 years of related experience, with 12+ years of Management experience.
  • BS Degree in Engineering, Business, Real Estate or related field is preferred.
  • 10+ years in-depth corporate real estate, preferably in a biotechnology, life sciences or pharmaceutical related industry.
  • Experience developing and driving measurable global real estate and workplace strategies.
  • Experience in FASB Lease Accounting and development of real estate financial models and business cases used to drive decisions.
  • Experience in negotiating real estate transactions as well as strong understanding of lease agreements.
  • Experience leading and managing teams and projects globally in a fast-paced and high-growth environment.
  • Proven ability to manage multi-million-dollar projects and budgets.
  • Proven ability to develop site master plans aligned with business goals.
  • Proven delivery of sustainability solutions supporting emission reduction goals.
  • Collaborative, able to integrate and bring together individuals under common goals and accountabilities.
  • Comfortable with dealing with ambiguity and continuing change in a fast paced and growing hi-tech company.
  • Proven experience in managing expenses and capital budgets in excess of 75M annually.
  • Proven experience in CPI tools and solutions as well as building a CPI culture.
Responsibilities
  • Lead the global Real Estate and Workplace Strategy Teams in developing Real Estate strategies and solutions that align with business unit strategies in delivering workplaces that fuel innovation, drive growth, and enhance employee experiences.
  • Oversee the entire lifecycle and negotiations of complex real estate transactions, from site selection and financial analysis to negotiation and execution, while also acting as an escalation point during the lifecycle of all real estate transactions, including build-out through the first day of business.
  • Support expansions and Mergers and Acquisition (M&A) activities including performance of due diligence and the identification, construction, and integration of new sites.
  • Develop annual and multi-year real estate plans in coordination with Finance, Legal, Procurement, and local operations teams.
  • Interact with executive management to inform and influence major real-estate strategies and decisions.
  • Provides directions to Real Estate construction team to create plans, budgets, and schedules facility purchases, construction and modifications, including estimates on equipment, labor, materials and other related costs.
  • Leads large scale contract development and negotiation pertaining to Real Estate in collaboration with Procurement and Legal teams. Work with Legal in development of Preferred Lease Term Library.
  • Keeps abreast of new workspace concepts, metrics, and industry best practices to drive innovation and collaboration and occupational efficiency.
  • Provides data and will partner with Finance for annual planning and budgets, and on-going financial management processes. Partners with accounting to ensure accurate FASB reporting.
  • Create and maintain strong business partnerships within the Real Estate industry bringing best practices into play and decision making.
  • Maintain an ongoing engagement and reporting program to monitor progress toward portfolio-wide sustainability goals and asset-level performance.
  • Accountable for supplier relationships with suppliers related as they relate to real estate strategies including Transaction Management, Professional Consulting Services, Design, etc.
  • Prepare and develop Global Real Estate & Global Facilities KPI’s and reports.
  • Lead, mentor, and manage the real estate team, including deal leads.
  • Manage a global lease database and reporting infrastructure while leading benchmarking and cost optimization initiatives.
  • Monitor market trends and implement real estate risk mitigation strategies such as consolidations and transitions.
  • Develop the Global Facilities & Real Estate Continuous Process Improvement Center of Excellence building a CPI culture of continuous improvement and standardization.
  • Develop the Workplace Strategy Center of Excellence to ensure identification and implementation of Workplace Strategies that optimize space utilization and efficiencies while creating a meaningful employee experience that is inspirational, innovative, and productive.
Desired Qualifications
  • Deep understanding of global real estate deal triggers, market impacts, financials and negotiation strategies.
  • Experience with identification and solicitation of global incentive opportunities
  • Lean or Six Sigma certification.
  • Background in workplace experience, sustainability, and hybrid workplace planning.

Illumina Accelerator helps create and grow genomics startups by partnering with venture investors and entrepreneurs as part of Illumina for Startups. It runs as a company-creation engine co-located with Illumina’s R&D sites in the San Francisco Bay Area and Cambridge, UK, offering mentorship, resources, and access to Illumina’s technology and networks. Its edge comes from Illumina’s sequencing tech, R&D resources, and a global network, plus a track record of 68 funded startups that have raised over $1 billion. The goal is to support ideas turning into market-ready genomics products and companies.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Clinical sequencing drives 65% of consumables revenue in Q1 2026.
  • D3b partnership analyzes 100,000 pediatric genomes for rare disease research.
  • USDA-FSIS adopts MiSeq i100 for foodborne pathogen WGS starting May 2026.

What critics are saying

  • Element Biosciences AVITI undercuts NovaSeq pricing by 70-80% per gigabase.
  • MGI Tech DNBSEQ captures 25% China market and expands globally.
  • Ultima Genomics UG 100 delivers 70% lower cost per genome at scale.

What makes Illumina unique

  • Illumina generates over 90% of world's DNA sequencing data.
  • NovaSeq X platform placed over 80 units in Q1 2026.
  • DRAGEN v4.5 reduces oncology false positives by over 90%.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
PR Newswire
Apr 14th, 2026
Illumina and D3b unite 100,000 pediatric genomes to accelerate rare disease and cancer research

Illumina and the Center for Data-Driven Discovery in Biomedicine have announced a data partnership to advance paediatric cancer and rare disease research. D3b is analysing 100,000 whole genomes from paediatric patients using Illumina software solutions, creating one of the largest unified genomic datasets ever assembled. The resulting insights will be made available through the Gabriella Miller Kids First Data Resource Centre, enabling researchers and clinicians to uncover biological origins of rare diseases and cancers. The dataset includes whole genomes from patients with rare congenital conditions and cancers, analysed using DRAGEN v4.4 and Illumina Connected Analytics. Additionally, Illumina is supporting D3b in the Pediatric Care eXpansion programme, which aims to reduce patient care journeys from months to weeks through a national data exchange spanning over 200 US paediatric institutions.

Food Safety Magazine
Apr 13th, 2026
USDA-FSIS updates WGS laboratory method.

USDA-FSIS updates WGS laboratory method. April 13, 2026 The U.S. Department of Agriculture's Food Safety and Inspection Service (USDA-FSIS) has updated its whole genome sequencing (WGS) laboratory method to incorporate the Illumina MiSeq i100 sequencing platform. MiSeq i100 represents the next generation of MiSeq sequencing instrumentation featuring integrated sequencing chemistry and substantially reduced runtimes. FSIS reports that this modernization enhances its laboratory system's ability to generate consistent, high-quality genomic data with increased laboratory sample throughput. The updated Microbiology Laboratory Guidebook (MLG) chapter 42, "Whole Genome Sequencing of Bacterial Isolates," now includes protocols for using both the Illumina MiSeq and MiSeq i100 platforms. FSIS will begin integrating the MiSeq i100 platform starting in May 2026, through the remainder of the fiscal year as existing laboratory supplies are exhausted and additional i100 units come online across FSIS laboratories. The current MiSeq instrumentation remains fully valid and equivalent for WGS analyses and will continue to be used where appropriate. WGS determines the full DNA sequence of an organism in a single laboratory protocol, and FSIS performs WGS on every bacterial isolate obtained from regulated food product and environmental samples. This publicly available data supports foodborne pathogen monitoring, food safety research, and other regulatory applications. FSIS notes that the inclusion of a specific commercial product in the MLG should not be considered an endorsement by the agency. Looking for quick answers on food safety topics? Try Ask FSM, our new smart AI search tool. Ask FSM SPONSORED BY Hi there. I'm Ask FSM. You can ask me anything about science-based solutions f The Food Safety Magazine editorial team comprises Bailee Henderson, Digital Editor | and Adrienne Blume, M.A., Editorial Director. JOIN TODAY to unlock your recommendations. Already have an account? Sign In

Yahoo Finance
Apr 9th, 2026
Illumina shares up 31.7% since October despite declining organic revenue and mediocre ROIC

Illumina has gained 31.7% since October 2025, reaching $126.99 per share, outpacing the S&P 500's 1.8% decline. Despite this performance, analysts cite three concerns about the genomics company. Illumina's organic revenue has declined an average of 1.1% year-on-year over the past two years, suggesting weakness in its core business. The company's earnings per share grew just 1.5% annually over five years, below its 6% revenue growth, indicating decreasing profitability. Additionally, its five-year average return on invested capital of 0.3% falls below typical healthcare sector costs. Trading at 24.7× forward price-to-earnings, the stock may present excessive downside risk despite recent gains, according to the analysis.

PR Newswire
Apr 2nd, 2026
Illumina board changes: Arnold, Epstein and Guthart to retire, King nominated

Illumina has announced changes to its board of directors ahead of its annual shareholder meeting. Frances Arnold, Robert S. Epstein and Gary S. Guthart will retire from the board, whilst the company has nominated David P. King for election as a new member. King brings extensive healthcare and life sciences experience as former executive chairman and CEO of Laboratory Corporation of America Holdings. He currently serves as director and chair of Privia Health and AmSurg Corporation, and as director of Smith & Nephew. Before joining LabCorp in 2001, King was a partner at Hogan & Hartson, where he led the firm's healthcare fraud and abuse practice. Board chair Scott Gottlieb praised the retiring directors' service and highlighted King's operating experience and regulatory insight across healthcare and life sciences.

Illumina
Mar 27th, 2026
Connect with Illumina at a major cancer research conference.

Connect with Illumina at a major cancer research conference. Details. Illumina will be exhibiting at the American Association for Cancer Research(R)(AACR) Annual Meeting 2026 in San Diego. Not affiliated with or endorsed by AACR. Learn how Illumina is driving innovation in cancer research and clinical solutions. Discover our latest advancements in single-cell, spatial, and multiomics technologies for research, and connect with our experts to learn about our cutting-edge IVD clinical testing solutions. Come explore our newest, disruptive single-cell and multiomics methods, designed to unlock game-changing discoveries in cancer research. Our booth and spotlight talk will showcase high-resolution microenvironment characterization and multiomics analysis methods that deliver deeper insights, without specialized equipment and at a fraction of the cost of alternative methods. Connect with our team to discover how these scalable technologies can accelerate every stage of cancer research and explore IVD clinical testing solutions available to your institution. Visit us at Illumina booth 4727 to learn more about how Illumina can help advance your research and clinical solutions. Schedule of Illumina events. Sunday, April 19. Exhibitor Spotlight Theater 1:30 PM-2:30 PM (PT) From circulating signals to spatial context: Multiomic insights for next-generation cancer research Location: Illumina Spotlight Theater B Multiomics is advancing cancer research at an unprecedented scale, opening new ways to understand disease and improving how we detect and track it. This symposium brings together two exciting areas driving that progress: multiomic liquid biopsy, combining DNA and methylation signals for deeper biological insights into disease detection and progression, and spatial transcriptomics, which helps reveal how cells are organized and interact within the tumor microenvironment (TME). We will share updates on Illumina innovations that connect these layers of biology, along with customer examples in 5-base, methylation-aware liquid biopsy, and spatially resolved expression mapping. Join us to explore how integrated multiomics can sharpen detection, bring tumor ecosystems into a clearer view, and accelerate translational discoveries. Featured speakers David Spencer, MD, PhD Assoc Professor, Division of Oncology Washington University School of Medicine Claire Mills, DDS, PhD Oral Health Sciences, University of Washington Fred Hutchinson Cancer Center, Setty & Beronja Labs Richard Capper, PhD Sr Director, Global Research Customer Marketing Illumina This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater are the opinions of the presenter and do not represent the position or the opinion of the American Association for Cancer Research(R)(AACR) or its members. Exhibit hours. Illumina booth 4727 * Sunday, April 19: 12 noon-5 PM (PT) * Monday, April 20: 9 AM-5 PM (PT) * Tuesday, April 21: 9 AM-5 PM (PT) * Wednesday, April 22: 9 AM-12 noon (PT) * Date & Time - Apr 19, 2026 - Apr 22, 2026 * Location - San Diego Convention Center Illumina booth 4727 San Diego, California * Topic - Cancer research, Oncology

INACTIVE